Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298915 · ClinicalTrials.gov registry record · Phase 3
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
A Phase 3 study, sponsored by University of Virginia.
- Not yet
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT07298915: Clinical Trial Phase 3 study, sponsored by University of Virginia.
NCT07298915 is a Phase 3 study that has not yet begun recruiting, run by University of Virginia. The registered enrollment target is 24 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07298915, a Phase 3 study, has not yet begun recruiting, sponsored by University of Virginia.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone * Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life Participants will: * Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician * (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training * Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures
Primary Outcome
Measurement will be taken 3 times and measured in kg. A positive value indicates an increase in weight and a negative value indicates a reduction in weight
Interventions
- DRUG Tirzepatide
- BEHAVIORAL Exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-08 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
What is known before NCT07298915 opens enrollment
NCT07298915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT07298915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07298915 about?
NCT07298915 is a clinical study titled "The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)". This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with weight loss medication...
What is the current status of trial NCT07298915?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2026-08. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07298915?
The interventions under investigation include: Tirzepatide (DRUG), Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT07298915?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07298915's enrollment target sits among peer trials
24 1943rd of 2000 higher than 49 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia